四氢喹啉 | 25448-04-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 四氢喹啉
• 英文名称: Einecs 246-995-7
• 英文别名: 3,4,7,8-tetrahydroquinoline
• CAS: 25448-04-8
• 化学式: C₉H₁₁N
• 分子量: 133.19
• InChiKey: UXUBCFFIVUBNOJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  12.4
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF
  申请人：SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

  公开号：US20170158680A1

  公开（公告）日：2017-06-08

  The present invention provides a heterocyclic compound represented by the formula (I), its stereoisomers, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and their use in preparing a medicament for the prevention and/or treatment of central nervous system disease.

  本发明提供了一种由公式（I）表示的杂环化合物，其立体异构体，或其药用可接受的盐，其药物组合物，以及它们用于制备预防或治疗中枢神经系统疾病的药物。
• SHP2 phosphatase inhibitors and methods of use thereof
  申请人：Relay Therapeutics, Inc.

  公开号：US10934302B1

  公开（公告）日：2021-03-02

  The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.

  本公开涉及新型化合物及其药物组合物，以及用本公开的化合物和组合物抑制SHP2磷酸酶活性的方法。本公开进一步涉及但不限于用本公开的化合物和组合物治疗与 SHP2 失调相关的疾病的方法。
• EP0789571A4
  申请人：——

  公开号：EP0789571A4

  公开（公告）日：1999-04-14
• CYCLIC AMIDINE ANALOGS AS INHIBITORS OF NITRIC OXIDE SYNTHASE
  申请人：MERCK & CO., INC.

  公开号：EP0789571A1

  公开（公告）日：1997-08-20
• SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
  申请人：Relay Therapeutics, Inc.

  公开号：US20220340576A1

  公开（公告）日：2022-10-27

  The present disclosure relates to novel compounds including formula (X) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.